Preclinical drug trial for CMT1A

English: Onion bulb formations in a nerve biop...

English: Onion bulb formations in a nerve biopsy in a case of HMSN type I (Charcot–Marie–Tooth disease) (Photo credit: Wikipedia)

 

ADX71441 has shown efficacy in multiple preclinical models including: CMT1A, Addex is also advancing several preclinical programs including: GABA-BR positive allosteric modulator (PAM) for Charcot-Marie-Tooth (type 1a) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder and other disorders.

About Addex Therapeutics

Addex Therapeutics (www.addextherapeutics.com) is a development stage company focused on advancing innovative oral small molecules against rare diseases utilizing its pioneering allosteric modulation-based drug discovery platform.

Resource:
http://www.marketwire.com/press-release/addex-receives-approval-ini…

 

 

 

 

Advertisements
This entry was posted in Charcot-Marie-Tooth disease and tagged , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s